Targets › B7H3
31 programs from 28 companies in 69 trials: 51 Phase 1, 12 Phase 3, 6 Phase 2; Oncology; next expected readout Dec 2026.
May participate in the regulation of T-cell-mediated immune response. May play a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. (UniProt, Q5ZPR3)
Open in Phaseline: the race on B7H3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Qilu Pharmaceutical | QLC5508 B7H3-targeting antibody-drug conjugate | B7H3 | Phase 3 | Esophageal Squamous Cell Carcinoma (ESCC); Extensive-stage Small Cell Lung Cancer; Refractory or Relapsed Solid Tumors; Advanced Prostate Cancer … | Dec 2026 |
| Daiichi Sankyo | Ifinatamab deruxtecan (DS-7300a, I-DXd) Anti-B7H3 antibody-drug conjugate | B7H3, DLL3 | Phase 3 | Small Cell Lung Cancer; Esophageal Squamous Cell Carcinoma; Extensive-stage Small-cell Lung Cancer; Advanced Solid Tumor … | Dec 2026 |
| Hansoh BioMedical R&D Company | HS-20093 anti-B7-H3 antibody-drug conjugate | B7H3, CD276 | Phase 3 | Osteosarcoma; Small Cell Lung Cancer; Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma … | Dec 2026 |
| MediLink Therapeutics (Suzhou) | YL201 B7H3-targeting antibody-drug conjugate | B7H3 | Phase 3 | Nasopharyngeal Carcinoma; Small Cell Lung Cancer; Advanced Esophageal Squamous Cell Carcinoma; SCLC, Extensive Stage … | Jan 2027 |
| CSPC Megalith Biopharmaceutical | SYS6043 B7-H3-targeted antibody-drug conjugate | B7H3 | Phase 3 | Platinum-resistant Ovarian Cancer; Advanced/Metastatic Solid Tumors | Dec 2027 |
| BioNTech SE | BNT324 B7-H3 antibody-drug conjugate | B7H3 | Phase 3 | Metastatic Castration-resistant Prostate Cancer; Advanced Lung Cancer | Sep 2028 |
| University College, London | hBRCA84D CAR T cells CAR-T cells targeting B7-H3 | B7H3, GD2 | Phase 1 | Neuroblastoma; Diffuse Midline Glioma, H3 K27M-Mutant; Sarcoma | Dec 2026 |
| Phrontline Biopharma | TJ101 EGFR/B7H3-directed antibody-drug conjugate with cleavable linker and novel topoisomerase I | EGFR, B7H3 | Phase 1 | Lung Cancer (NSCLC) | Dec 2026 |
| Peking University People's Hospital | B7H3-IRDye800CW Anti-B7H3 antibody conjugated to IRDye800CW fluorophore for near-infrared imaging of B7-H3 | B7H3 | Phase 1 | Osteosarcoma | Dec 2026 |
| The Affiliated Hospital of Xuzhou Medical University | fhB7H3.CAR-Ts B7H3-targeting chimeric antigen receptor T cells | B7H3 | Phase 1 | Hepatocellular Carcinoma | Feb 2027 |
| St. Jude Children's Research Hospital | B7-H3-CAR T Cells B7-H3-targeted chimeric antigen receptor T cell therapy | B7H3 | Phase 1 | Pediatric Solid Tumor; Central Nervous System Neoplasms; Sarcoma | Mar 2027 |
| Seattle Children's Hospital | SCRI-CARB7H3(s) B7H3-specific chimeric antigen receptor (CAR) T cell | B7H3 | Phase 1 | Central Nervous System Tumor | May 2027 |
| Tcelltech | TX103 Anti-B7-H3 chimeric antigen receptor T-cell (CAR-T cell) therapy | B7H3 | Phase 1 | High-grade Glioma; Solid Tumors | Jun 2027 |
| IDEAYA Biosciences | IDE034 Bispecific antibody targeting B7-H3 and PTK7 | B7H3, PTK7 | Phase 1 | Esophageal Squamous Cell Carcinoma | Jul 2027 |
| Sun Yat-Sen University Cancer Center | GD2/B7H3 CAR-T cell therapy Dual-targeted CAR-T cells recognizing GD2 and B7H3 antigens | GYPC, B7H3 | Phase 1 | Neuroblastoma (NB) | Dec 2027 |
| Radiopharm Theranostics | 177Lu-BetaBart Lutetium-177 labeled anti-B7-H3 monoclonal antibody | B7H3 | Phase 1 | Castration-Resistant Prostate Cancer (CRPC) | Dec 2027 |
| Dushu Lake Hospital Affiliated to Soochow University | Allogeneic B7-H3 CAR-γδT cell (QH104) B7-H3-targeted CAR-γδT cell therapy | B7H3 | Phase 1 | Brain Gliomas | Dec 2027 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | EPC-003 Fully Human Anti-B7H3/IL13Ra2 Armored CAR-T Cell Therapy Bispecific CAR-T cell therapy targeting B7H3 and IL13Ra2 | B7H3, IL13RA2 | Phase 1 | Refractory Glioblastoma | Dec 2027 |
| Eastern Hepatobiliary Surgery Hospital | Super Hi-TCR-T cells Multi-target TCR-engineered T cells targeting Nectin4, NKG2DL, TROP2, B7H3, GPC3, and FAP | PVRL4, KLRC1, TROP2, B7H3, GPC3 | Phase 1 | Advanced Hepatocellular Carcinoma (HCC) | Jan 2028 |
| UNC Lineberger Comprehensive Cancer Center | iC9-CAR.B7-H3 T cell infusion Chimeric antigen receptor T cells targeting B7-H3 | B7H3 | Phase 1 | Pancreas Cancer; Epithelial Ovarian Cancer | Apr 2028 |
| UNC Lineberger Comprehensive Cancer Center | iC9-CAR.B7-H3 T cells CAR-T cells targeting B7-H3 antigen | B7H3 | Phase 1 | Breast Cancer; Ovary Neoplasm | May 2028 |
| Aktis Oncology | [64Cu]Cu-AKY-2519 anti-B7-H3 targeted imaging agent (copper-64 PET tracer) | B7H3 | Phase 1 | NSCLC | Dec 2028 |
| NEOK Bio | NEOK001 B7-H3 and ROR1 targeting bispecific antibody-drug conjugate | B7H3, ROR1 | Phase 1 | Locally Advanced (Unresectable) or Metastatic Solid Tumors | Jan 2029 |
| Suzhou Maximum Bio-tech | MT027 B7H3-specific CAR-T cells | B7H3 | Phase 1 | Advanced Malignant Solid Tumor | Feb 2029 |
| Conjupro Biotherapeutics | SYS6043 Anti-B7-H3 antibody-drug conjugate | B7H3 | Phase 1 | Cancer | Dec 2029 |
| BioNTech SE | anti-B7-H3 antibody conjugated to topoisomerase I inhibitor anti-B7-H3 antibody-drug conjugate with topoisomerase I inhibitor | B7H3 | Phase 1 | Non-Small Cell Lung Cancer | Feb 2030 |
| Masonic Cancer Center, University of Minnesota | GTB-5550 B7-H3-targeted natural killer cell engager (TriSpecific Killer Engager, TriKE) | B7H3 | Phase 1 | Tri-specific Killer Engager | Jan 2031 |
| PersonGen BioTherapeutics (Suzhou) | TAA06 Injection B7-H3-targeted CAR-T cell therapy | B7H3 | Phase 1 | B7-H3-positive Relapsed/ Refractory Neuroblastoma | Feb 2039 |
| Seattle Children's Hospital | second generation 4-1BBζ B7H3-EGFRt-DHFR Dual-targeted CAR T cell therapy directed at B7H3 and CD19 with 4-1BB costimulatory domain | B7H3, CD19 | Phase 1 | Pediatric Solid Tumor | Dec 2040 |
| Children's National Research Institute | B7-H3 CAR T cells B7-H3-targeting CAR T cells | B7H3 | Phase 1 | Rhabdomyosarcoma | Dec 2041 |
| Chulalongkorn University | B7H3 specific CAR T cell with IL-7Ra signaling domain Anti-B7H3 CAR-T cell therapy with IL-7 receptor alpha co-stimulatory signaling domain | B7H3, IL7RA | Phase 1 | DIPG Brain Tumor | – |
Advanced Solid Tumor (6) Osteosarcoma (3) Small Cell Lung Cancer (3) Pediatric Solid Tumor (3) Non-Small Cell Lung Cancer (2) Advanced Solid Tumors (2) Advanced Prostate Cancer (2) Esophageal Squamous Cell Carcinoma (2) Sarcoma (2) Head and Neck Squamous Cell Carcinoma (1) Advanced Gastric and Gastroesophageal Junction Adenocarcinoma (1) Metastatic Colorectal Cancer (CRC) (1)
other (12), small molecule (11), mixed (5), antibody (3)
UNC Lineberger Comprehensive Cancer Center (2) Seattle Children's Hospital (2) BioNTech SE (2) Hansoh BioMedical R&D Company (1) Daiichi Sankyo (1) Qilu Pharmaceutical (1) St. Jude Children's Research Hospital (1) IDEAYA Biosciences (1) The Affiliated Hospital of Xuzhou Medical University (1) Chulalongkorn University (1) Masonic Cancer Center, University of Minnesota (1) MediLink Therapeutics (Suzhou) (1) CSPC Megalith Biopharmaceutical (1) University College, London (1) Phrontline Biopharma (1) Aktis Oncology (1) NEOK Bio (1) Peking University People's Hospital (1) Dushu Lake Hospital Affiliated to Soochow University (1) Conjupro Biotherapeutics (1)
CD276 (1) DLL3 (1) PTK7 (1) IL7RA (1) GD2 (1) EGFR (1) ROR1 (1) CD19 (1) IL13RA2 (1) PVRL4 (1) KLRC1 (1) TROP2 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.